Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-03T03:20:21.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces the transition from “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-27T06:34:18.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-20T06:41:08.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The revision number in the footer changes from v3.7.0 to v3.7.1 while the study record remains unavailable.
    Difference
    0.2%
    Check dated 2026-10-13T08:13:09.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The study record page is replaced by a 403 Forbidden message, with a Home link.
    Difference
    0.5%
    Check dated 2026-10-06T08:29:22.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error screen with a minimal header and a Home link, replacing the study details. It indicates restricted access to the record rather than a content update to the study information.
    Difference
    18%
    Check dated 2026-09-22T07:00:11.000Z thumbnail image

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.